AURA
Aura Biosciences Inc
NASDAQ: AURA · HEALTHCARE · BIOTECHNOLOGY
$7.05
+4.75% today
Updated 2026-04-30
Market cap
$432.06M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.76
Dividend yield
—
52W range
$4 – $8
Volume
0.3M
Aura Biosciences Inc (AURA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — |
| Cost of revenue | $509000.00 | $831000.00 | $835000.00 | $1.18M | $1.29M | $1.22M | — |
| Gross profit | $-509000.00 | $-831000.00 | $-835000.00 | $-1.18M | $-1.29M | $-1.22M | — |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $19.11M | $18.04M | $25.16M | $42.24M | $63.94M | $73.30M | $90.30M |
| SG&A | $4.52M | $4.16M | $10.09M | $18.06M | $19.76M | $22.81M | $22.49M |
| Operating income | $-24.14M | $-22.21M | $-35.25M | $-60.30M | $-84.99M | $-96.12M | $-112.79M |
| Operating margin | — | — | — | — | — | — | — |
| EBITDA | $-23.69M | $-21.38M | $-34.42M | $-59.12M | $-83.70M | $-94.89M | $-111.66M |
| EBITDA margin | — | — | — | — | — | — | — |
| EBIT | $-24.20M | $-22.21M | $-35.25M | $-60.30M | $-84.99M | $-96.12M | $-112.79M |
| Interest expense | $5000.00 | $3000.00 | $13000.00 | $850000.00 | — | — | — |
| Income tax | $5000.00 | $3000.00 | $-830000.00 | $-1.53M | $137000.00 | $112000.00 | — |
| Effective tax rate | -0.0% | -0.0% | 2.3% | 2.5% | -0.2% | -0.1% | 0.0% |
| Net income | $-24.20M | $-22.21M | $-35.25M | $-58.76M | $-76.41M | $-86.92M | $-106.19M |
| Net income growth (YoY) | — | +8.2% | -58.7% | -66.7% | -30.0% | -13.8% | -22.2% |
| Profit margin | — | — | — | — | — | — | — |